Stockreport

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]

Sana Biotechnology, Inc.  (SANA) 
PDF Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect to report additional data in 2024 Enrolling patients in the ongoing GLEAM trial for SC291 in B [Read more]